Company intelligence / Profile preview

Ophthagenics

Ownership: Private
Development stage: Other

Overview

Ophthagenics is an early-stage biotechnology company focused on developing innovative therapies and delivery systems for ophthalmic diseases. The company specializes in creating sustained-release formulations designed to improve the treatment of chronic eye conditions such as age-related macular degeneration and glaucoma. By leveraging advanced drug delivery technologies, Ophthagenics aims to reduce the frequency of intraocular injections and enhance patient compliance and outcomes. Their research pipeline includes novel small molecule candidates and proprietary delivery platforms targeting vascular and degenerative ocular pathologies.

Therapeutic areas: Ophthalmology
Modalities: Small moleculeDrug delivery system
Industry: Biotech

Beyond the preview

Go deeper on Ophthagenics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ophthagenics.

Explore the full profile